SELPLG and plasma cell myeloma: An in vivo evidence emerged in 2013 where Zheng et al. showed that TAMs contributed to myeloma drug resistance through P-selectin glycoprotein ligand-1 (PSGL-1)/selectins and intercellular adhesion molecule-1 (ICAM-1)/CD18 contact-dependent interactions.